Catalent embarks on $230M viral vector expansion project at Harmans campus

By completion at the end of 2022, the campus will accommodate 18 cGMP viral vector manufacturing suites

The company has cited growing customer demand as the impetus behind this latest investment.

The Harmans campus includes a fully operational FDA- and EMA-approved facility comprising 10 commercial-scale manufacturing suites.

A second facility, which is already under construction following an initial $130 million investment by Catalent in 2020, will add five new manufacturing suites. These are expected to be operational mid-2022.

The latest investment will see the company construct three additional multiroom commercial suites, and expand the site’s storage capabilities for just-in-time inventory space, ultra-low temperature freezers and its water-for-injection infrastructure.

When complete at the end of 2022, the campus will house a total of 18 cGMP viral vector manufacturing suites, each designed to accommodate multiple bioreactors up to 2,000-L and enable the execution of commercial manufacturing from cell bank to purified drug substance.

Furthermore, the expansion will create more than 700 new technical, scientific, and operational employment positions during the next 6 years.